Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthr...

Descripción completa

Detalles Bibliográficos
Autores: Montes, Ariana, Pérez-Pampin, Eva, Navarro-Sarabia, Federico, Moreira, Virginia, Rodríguez de la Serna, Arturo, Magallares, Berta, Vasilopoulos, Yiannis, Sarafidou, Theologia, Fernández-Nebro, Antonio, Ordóñez, María del Carmen, Narváez, Javier, Cañete, Juan D., Márquez, Ana, Pascual-Salcedo, Dora, Joven, Beatriz, Carreira, Patricia, Moreno-Ramos, Manuel J., Caliz, Rafael, Ferrer, Miguel Ángel, GarcÍa-Portales, Rosa, Blanco, Francisco J., Magro, Cesar, Raya, Enrique, Valor, Lara, Alegre-Sancho, Juan J., Balsa Criado, Alejandro, Martín, Javier, Plant, Darren, Isaacs, John, Morgan, Ann W., Barton, Anne, Wilson, Anthony G., Gómez-Reino, Juan J., González, Antonio
Tipo de recurso: artículo
Fecha de publicación:2015
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/672347
Acceso en línea:http://hdl.handle.net/10486/672347
https://dx.doi.org/10.1186/s13075-015-0571-z
Access Level:acceso abierto
Palabra clave:Rheumatoid arthritis
Treatment
IgG1 allotype
Medicina
Descripción
Sumario:Introduction: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). Methods: The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League Against Rheumatism (EULAR) response criteria. Results: An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. Conclusions: Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA

Similares en LA Referencia